News Articles Tagged: Preclinical Cancer Models

Exploring the Efficacy of GSK2636771 in Preclinical Cancer Models

Investigate the preclinical efficacy of GSK2636771, a selective PI3K beta inhibitor, in various cancer models and its potential in advancing targeted cancer therapies.

CB-839: A Versatile GLS1 Inhibitor for Preclinical Oncology Studies

Discover the preclinical applications of CB-839, a potent glutaminase GLS1 inhibitor, in various cancer models and combination therapies.

Ipatasertib in Vivo: Demonstrating Antitumor Activity in Preclinical Models

Examine the in vivo efficacy of Ipatasertib in preclinical cancer models, highlighting its antitumor effects and the critical role of PUMA.